# NASVAC Phase-III Trial in Chronic Hepatitis B (CHB) Patients

> **NCT01374308** · PHASE3 · UNKNOWN · sponsor: **Clinical Research Organization, Dhaka, Bangladesh** · enrollment: 160 (estimated)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **BIOLOGICAL:** NASVAC
- **DRUG:** Pegylated interferon alpha 2b

## Key facts

- **NCT ID:** NCT01374308
- **Lead sponsor:** Clinical Research Organization, Dhaka, Bangladesh
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-06
- **Primary completion:** 2013-06
- **Final completion:** 2013-12
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2012-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01374308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01374308, "NASVAC Phase-III Trial in Chronic Hepatitis B (CHB) Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01374308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*